Replies to post #250904 on Biotech Values

[DewDiligence]

Based on today's dataset, AKRO is seeking to resuscitate the failed phase-2 trial in cirrhotic NASH:

https://www.fiercebiotech.com/biotech/akero-bruised-earlier-failure-soars-liver-scarring-improves-longer-mash-trial

The deepening responses seen between Week 24 and Week 96 bode well for the Akero study that failed last year. At the time, Akero argued showing a statistically significant improvement in fibrosis by Week 36 was a “high bar.” The biotech is tracking participants in the failed trial through Week 96, suggesting it may reverse the failure at a later readout if responses improve over time. Results are due next year.

[DewDiligence]

AKRO seeking $345M* in underwritten offering:

https://www.globenewswire.com/news-release/2024/03/04/2839994/0/en/Akero-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock.html

*Assuming exercise of underwriter’s option.

[DewDiligence]

B-I has_a fusion protein_for NASH that_hits GLP-1/FGF21:

https://www.genengnews.com/news/boehringer-ingelheim-yuhan-launch-up-to-870m-nash-collaboration/

Could be an alternative to combination therapy.